Innovation and Development in the Medical Device Space: Diabetes, Ophthalmic Industries Making Further Advancements and Creating New Technologies

Wall Street Transcript

67 WALL STREET, New York - August 2, 2013 - The Wall Street Transcript has just published its Medical Devices Report offering a timely review of the sector to serious investors and industry executives. This special feature contains expert industry commentary through in-depth interviews with public company CEOs and Equity Analysts. The full issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Topics covered: Orthopedics and Cardiovascular Medical Devices - Medical Device Innovation and Consolidation Trends - Cardiac - Health Care - Affordable Care Act - Continued Pricing Pressure - Aging U.S. Population

Companies include: DexCom, Inc. (DXCM), Endologix Inc. (ELGX), STAAR Surgical Company (STAA), Nxstage Medical, Inc. (NXTM) and many more.

In the following excerpt from the Medical Devices Report, an expert analyst discusses the outlook for the sector for investors:

TWST: When you look at the industry, where are the new opportunities? Are there new spaces or devices that are coming down the road that look attractive?

Mr. Cooley: I definitely think there are. We have seen some exciting developments in diabetes care with further advancement in sensor technology in public companies like Dexcom (DXCM). Private companies like Tandem Diabetes Care have made insulin pump usage far more user friendly, and quite frankly dispensing the insulin more efficiently through a siphoning system.

We've seen some tremendous innovation in the ophthalmic industry as a whole in terms of new lens-based technologies for cataract patients and those that want to undergo a refractive option from a lens-based modality. And we are clearly seeing, as always, in the cardiac space great innovation there as well.

One company that comes to mind is Endologix (ELGX) - two new devices, one the Nellix system, the other Ventana, both of which really stand to expand the market for endovascular grafts treating abdominal aortic anerysms, or AAA. There's always going to be innovation here in the space.

TWST: So there is no lack of new product coming to market despite the changes?

Mr. Cooley: Correct. The medical device industry is all about innovation, and that's continuing. I just think it emphasizes the need for that innovation going forward as against things that just really don't add value.

TWST: Earlier on you mentioned the higher costs of bringing product to market. Does the industry have the balance sheet to support that?

For more of this interview and many others visit the Wall Street Transcript - a unique service for investors and industry researchers - providing fresh commentary and insight through verbatim interviews with CEOs, portfolio managers and research analysts. This special issue is available by calling (212) 952-7433 or via The Wall Street Transcript Online.

Rates

View Comments